Clinical Trial Detail

NCT ID NCT01197170
Title Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

Advanced Solid Tumor

Therapies

Erlotinib

Everolimus

Sorafenib

Anastrozole

Bevacizumab

Age Groups: adult senior

No variant requirements are available.